Menu
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024. Outset Medical describes itself as a “medical technology company.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. Jetzt den vollständigen Artikel lesen
Robbins LLP is Investigating Allegations that Outset Medical, Inc. (OM) Misled Investors Regarding its Business Prospects
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Porcelli v. Outset Medical, Inc., et al., Case No. 5:24-cv-06124, on behalf of persons and entities that purchased or otherwise acquired Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) securities Jetzt den vollständigen Artikel lesen
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) securities between August 1, 2022 and August 7, 2024, inclusive (the “Class Period”). Outset Medical investors have until October 28, 2024 to file a lead plaintiff motion. Investors suffering Jetzt den vollständigen Artikel lesen
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Porcelli v. Outset Medical, Inc., et al., Case No. 24cv6124, on behalf of persons and entities that purchased or otherwise acquired Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) securities Jetzt den vollständigen Artikel lesen
https://www.investing.com/news/company-news/outset-medical-stock-hits-52week-low-at-057-amid-steep-decline-93CH-3594058
Outset Medical (OM) has shared an update. Jim Hinrichs resigned from his positions on the Board and as Audit Committee Chair of Outset Medical, Inc…
https://www.investing.com/news/company-news/outset-medical-ceo-leslie-trigg-sells-shares-worth-over-4400-93CH-3574806
NEW YORK, Aug. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/OM .
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Outset investments or would like to inquire about potentially pursuing Jetzt den vollständigen Artikel lesen